26 Sep 2026

CRC Research Update — September 26, 2026

Creator: The CRC Digest
Published: 2026-09-26T11:26:04Z

Today's colorectal cancer research highlights

1 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

TREATMENT
FOLFOX rechallenge matched regorafenib in third-line metastatic CRC
A retrospective study of 122 patients with left-sided, RAS/BRAF wild-type mCRC found that third-line FOLFOX plus bevacizumab rechallenge showed similar outcomes to regorafenib, with the oxaliplatin-free interval potentially influencing treatment response. (Cancers)
RESEARCH
Circulating tumor DNA tumor fraction predicts anti-EGFR rechallenge response
In the CAVE-2 GOIM trial, patients with "negative" ctDNA had a 12% response rate and median progression-free survival of 5.6 months with rechallenge with cetuximab ± avelumab, compared to 3% and 3.65 months in "positive hyperselected" patients. (J Liq Biopsy)
RESEARCH
MSI/MMR testing may show discordant results between tissue and blood
A review highlights that MSI/MMR assessment can yield discordant results across assays, anatomic sites, or time points, including cases where tissue shows MSS/pMMR but circulating tumor DNA indicates MSI-H. (Cancers)
RESEARCH
AI platforms predict molecular alterations from routine pathology slides
A review of 30 studies found that artificial intelligence platforms can detect MSI, MMR status, and mutations in BRAF, KRAS, NRAS, and TP53 from hematoxylin and eosin-stained slides, potentially reducing cost and turnaround time. (Int J Mol Sci)

🧬 Biomarker Spotlight

Research by genetic subtype. KRAS, BRAF, MSI-H, HER2, and more

Inflammation markers predict outcomes in RAS/BRAF wild-type mCRC on anti-EGFR therapy
A real-world cohort study examined neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammation index as prognostic markers in patients receiving anti-EGFR therapy. (Colorectal Dis)

This week's research focuses on refining biomarker testing and treatment sequencing in advanced disease.

Get CRC research intelligence delivered weekly, free.

Browse by Topic

KRAS Mutations Immunotherapy (MSI-H)BRAF Early-Onset / Under 50 Liver Metastases Clinical Trials Living with CRC All Issues

CRC Research Update

Subscribe to The CRC Digest